glp-1 agonists australia Supporting patients through agonist cessation effects Retatrutide in Australia: Weight Management

material, see support primary care staff in managing adult patients on these medications

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists

To bypass the pharmacological challenges associated with unspecific blocking of NMDA receptors, we designed a peptidedrug conjugate comprising the NMDA receptor antagonist MK-801 and a GLP-1 peptide analogue

Danuglipron (Pfizer) is another oral GLP-1 currently in phase 2 trials, and CT-996 (Carmot Therapeutics) is in phase 1 trials

Taken together, these findings suggest that GLP-1RAs are poised to reshape the therapeutic landscape by integrating metabolic, cardiovascular, renal, hepatic, and potentially neurological benefits

Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: The SURPASS-6 randomized clinical trial: The SURPASS-6 randomized clinical trial